MIM
ACOR

MetLife Investment Management’s Acorda Therapeutics ACOR Stock Holding History

MetLife Investment Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-170
Closed -$157K – 2418
2019
Q2 		$157K Hold
170
– – ﹤0.01% 2168
2019
Q1 		$272K Hold
170
– – ﹤0.01% 1812
2018
Q4 		$319K Hold
170
– – ﹤0.01% 1638
2018
Q3 		$402K Hold
170
– – ﹤0.01% 1668
2018
Q2 		$587K Hold
170
– – 0.01% 1311
2018
Q1 		$484K Hold
170
– – 0.01% 1388
2017
Q4 		$439K Buy
+170
New +$483K 0.01% 1472

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's ACOR Position: Q3 2019 in Review

MetLife Investment Management sold out of Acorda Therapeutics (ACOR) in Q3 2019, closing a stake of 170 shares — an estimated $157K sold.

MetLife Investment Management first reported a position in ACOR in Q4 2017 and held it in 7 quarters. The position peaked at $587K in Q2 2018. 151 funds tracked by Wall St. Rank hold ACOR as of Q3 2019.

  • MetLife Investment Management reported no remaining Acorda Therapeutics position as of Q3 2019 after selling out during the quarter.
  • MetLife Investment Management sold 170 Acorda Therapeutics shares in Q3 2019, an estimated $157K.
  • MetLife Investment Management first reported a position in Acorda Therapeutics in Q4 2017 and held it in 7 quarters.
  • MetLife Investment Management's Acorda Therapeutics position peaked at $587K in Q2 2018.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2019.

Based on MetLife Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.